title: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
abstract: Simavastatin (MK-733, Zocor, CAS 79902-63-9), a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, was administered for a period of at least 3 years to 21 patients suffering from primary hypercholesterolemia. Significant decreases were noted for plasma cholesterol (30%), low density lipoprotein cholesterol (40%), whereas an increase in plasma high density lipoprotein cholesterol (11%) was observed. The drug therapy was well tolerated and clinical examinations revealed no adverse effects. No development of cataracts or other ocular side effects have been observed during this 3-year follow-up period.
authors.affiliation: Department of Ophthalmology, University of Göttingen, Fed. Rep. of Germany.
authors.forename: W
authors.initials: W
authors.lastname: Behrens-Baumann
authors.forename: J
authors.initials: J
authors.lastname: Thiery
authors.forename: E
authors.initials: E
authors.lastname: Wieland
authors.forename: H G
authors.initials: HG
authors.lastname: Fieseler
authors.forename: D
authors.initials: D
authors.lastname: Seidel
mesh_terms: D000328:Adult; D000368:Aged; D002386:Cataract / Q000139:chemically induced* / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D007908:Lens, Crystalline / Q000187:drug effects* / Q000473:pathology; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin